About the Company
Catalyst is a clinical-stage biopharmaceutical company leveraging exceptional science to discover and develop essential medicines.
Catalyst is focused on creating and commercializing novel medicines to address serious medical conditions for patients who need new or better treatment options.
Engineered proteases can efficiently initiate or regulate protease-driven biological cascades and can act on hundreds to thousands of target molecules.
While our scientific approach is singularly focused on protease therapeutic agents, our opportunities are many. Learn more about Our Pipeline.
A protease is an enzyme that cleaves target proteins. Learn more about Our Science.
— CB 2679d/ISU304 has patent coverage in all key commercial territories — SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), today announced that it has been issued patents covering its coagulation Factor IX...
— CB 2679d/ISU304 is approximately 22 times more potent than current hemophilia B therapy — SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), today announced positive clinical data from the first Cohort of...
Catalyst Biosciences Reports Second Quarter 2017 Financial Results and Provides Subcutaneous (SQ) Hemophilia Program Update
— Enrollment into Phase 1/2 trial of Factor IX SQ candidate CB 2679d is ongoing; trial is on track to announce interim results by year-end — — Raised $26 Million from Financing Activities through the Second Quarter; Ended Q2 with...
SOUTH SAN FRANCISCO, Calif., July 06, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a financial milestone under its collaboration...